Chronic Kidney Disease Japan Cohort (CKD-JAC) Study
Not Applicable
- Conditions
- Chronic Kidney Disease
- Registration Number
- JPRN-UMIN000020038
- Lead Sponsor
- Kyowa Hakko Kirin Co., Ltd.
- Brief Summary
Refer to the article 1.Primary Endpoint:Renal event https://www.ncbi.nlm.nih.gov/pubmed/27412450 2.Primary Endpoint:CVD https://www.ncbi.nlm.nih.gov/pubmed/27884399
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 3000
Inclusion Criteria
Not provided
Exclusion Criteria
1.liver cirrhosis 2.HIV/AIDS 3.transplant recipients and patients 4.polycystic kidney disease 5.cancer
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The primary outcomes are progression of CKD defined by reduction in eGFR, CVD events and all cause mortality
- Secondary Outcome Measures
Name Time Method The secondary outcomes are QOL and hospitalization.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie renal progression in JPRN-UMIN000020038 CKD-JAC cohort study?
How does CKD-JAC compare to other cohorts in identifying CVD risk factors for chronic kidney disease?
What biomarkers are associated with adverse events in JPRN-UMIN000020038 CKD-JAC study participants?
Are there novel drug targets identified through CKD-JAC's observational data on renal and cardiovascular endpoints?
What combination therapies show promise for managing CKD-related cardiovascular complications based on CKD-JAC findings?